SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The world's lightest blockchain, powered by participants. Mina is building a privacy-preserving gateway between the real world and crypto — and the infrastructure for the secure, democratic future we all deserve.

Mina Protocol

Mina Protocol is experiencing heightened interest, with community members actively discussing potential price movements and entry points. Some traders believe it's poised for a breakout, while others express concerns about its business development and tokenomics. Recent developments around zero-knowledge proofs and partnerships, along with its unique 'light' blockchain, are also being weighed by investors.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as the community discusses its recent price action, potential bottom, and upcoming earnings report. Call options activity and LEAPS are being highlighted, while some traders debate the stock's valuation and potential for a run-up. Additionally, some analysts are weighing in with price target adjustments.

Tidal Trust II - Defiance Daily Target 2X Long HIMS ETF

Defiance Daily Target 2X Long HIMS ETF

The Defiance Daily Target 2X Long HIMS ETF ($HIMZ) is trending due to increased attention and speculative trading, amplified by its leveraged nature. Community discussions revolve around potential for significant gains, with some highlighting potential short squeezes and others noting the risks associated with leveraged ETFs and potential tracking discrepancies with $HIMS. Some traders express bullish sentiments, looking for the ETF to double their gains.

BlackRock Institutional Trust Company N.A. - iShares Russell 1000 Growth ETF

iShares Russell 1000 Growth ETF

IWF is trending amid discussions about growth versus value stocks and potential rotations in market leadership. Options activity suggests some investors anticipate continued upside, while others are hedging against potential declines. Community members are analyzing technical indicators and ETF flows to gauge the strength and direction of the Russell 1000 Growth ETF.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin (FIL) is experiencing increased interest as traders discuss its potential in decentralized storage, particularly with growing demand from AI and Web3 projects. Community members are weighing the potential for significant returns against concerns about its past performance and circulating supply. Some see FIL as undervalued, while others are looking at alternative coins.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain and as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is trending amid mixed community sentiment, with some users expressing frustration over recent price action and labeling it a "scam coin." However, others point to upcoming catalysts like the Goliath mainnet launch and growing holder numbers, suggesting potential for future growth and real-world utility, particularly in the institutional finance sector.

Southwest Airlines Co. engages in the operation and management of a passenger airline. The firm also offers ancillary services such as early bird check-in, upgraded boarding, and transportation of pets and unaccompanied minors. It operates in the United States, the Commonwealth of Puerto Rico, Mexico, Jamaica, the Bahamas, Aruba, Dominican Republic, Costa Rica, Belize, Cuba, the Cayman Islands, and Turks and Caicos. The company was founded by Rollin W. King and Herbert D. Kelleher on March 9, 1967 and is headquartered in Dallas, TX.

Southwest Airlines Co

Southwest Airlines is trending due to a mix of reactions to announced policy changes, including the introduction of baggage fees and a basic economy fare, intended to boost revenue under pressure from activist investor Elliott Management. While some investors are optimistic about the potential for increased profitability, the community is concerned about the impact on customer loyalty and brand perception as Southwest moves away from its traditional value proposition.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community debates its future following comments from Ripple's CTO on decentralization and utility, while also anticipating potential developments such as an XRP spot ETF.  Some traders express frustration with price stagnation and discuss alternate investments, while others remain optimistic, citing potential catalysts and long-term growth prospects.  The crypto market and XRP specifically is sensitive to macro conditions such as the government shutdown and the potential for regulation.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye ($MBLY) is trending amid mixed sentiment, with some traders highlighting trendline support and potential short squeezes, while others express bearish views citing Intel's shareholding and recent price declines despite positive catalysts. Community members are actively debating the company's technology in ADAS and autonomous driving, partnerships, and future prospects, particularly regarding the robotaxi business and competition within the sector.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is trending amidst discussions about its valuation, Medicare Advantage plans, and potential partnerships, particularly with Clover Health. The stock's volatile price action and perceived manipulation are also key talking points among investors. Some analysts suggest the recent pullback is an overreaction and highlight the company's long-term potential and attractive entry points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow 

Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo (Lenacapavir)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo (lenacapavir), the companys...

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of +14.88% and +4.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences Announces Third Quarter 2025 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2025 results of operations. We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing...

Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?

Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for These 5 Pharma Bigwigs This Earnings Season?

As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit

Key Events This Extremely Busy Week: Central Banks, Earnings Galore, And Trump-Xi Summit As noted earlier, investors face a monumentally important and extremely busy week ahead that includes rates...

Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

$GILD Q3 &#39;25 Earnings Results &amp; Recap

Gilead&#39;s Q3 2025 earnings beat EPS estimates at $2.47 (or $2.22 excluding a one-time item), and revenue was $7.3 billion, slightly below the $7.45B estimate; the company is increasing its full-year HIV revenue growth expectations to approximately 5%, while forecasting cell therapy to decline approximately 10% for the full year.

Stocktwits

Gilead Sciences, Inc.

 Q3 '25 Earnings Results & Recap

Gilead's Q3 2025 earnings beat EPS estimates at $2.47 (or $2.22 excluding a one-time item), and revenue was $7.3 billion, slightly below the $7.45B estimate; the company is increasing its full-year HIV revenue growth expectations to approximately 5%, while forecasting cell therapy to decline approximately 10% for the full year.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$118.89
Prev Close	$118.44
Open	$116.06
Dividend Yield	3.33%
50-Day Moving Average	$115.69
Beta	0.36
Avg. Volume	7.21M
PE Ratio	23.83

52-Week High	$124.61
52-Week Low	$86.08
Market Capitalization	$148.64B
EPS (Annual)	$0.3825
Price to Book	7.56
Revenue Per Employee	$1.63M
Enterprise Value/EBITDA	N/A

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GILD News

GILDGilead Sciences, Inc.